The historical rank and industry rank for Mangalam Drugs & Organics's FCF Margin % or its related term are showing as below:
NSE:MANGALAM'
s FCF Margin % Range Over the Past 10 Years
Min: -3.33 Med: 2.07 Max: 8.37
Current: -3.33
During the past 13 years, the highest FCF Margin % of Mangalam Drugs & Organics was 8.37%. The lowest was -3.33%. And the median was 2.07%.
NSE:MANGALAM's FCF Margin % is ranked worse than 65.24% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs NSE:MANGALAM: -3.33
Mangalam Drugs & Organics FCF Margin % Related Terms
Mangalam Drugs & Organics FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangalam Drugs & Organics FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Mangalam Drugs & Organics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangalam Drugs & Organics (NSE:MANGALAM) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mangalam Drugs & Organics and its competitors. According to the industry distribution chart, Mangalam Drugs & Organics ranks #625 out of 958 companies in the Drug Manufacturers industry, placing it in the top 65.2%.
Is Mangalam Drugs & Organics' FCF Margin % too high?
Mangalam Drugs & Organics' current FCF Margin % is 0.00%. Based on the distribution chart, Mangalam Drugs & Organics ranks #625 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Mangalam Drugs & Organics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mangalam Drugs & Organics ranks #625 out of 958 companies for FCF Margin %. This places Mangalam Drugs & Organics in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mangalam Drugs & Organics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangalam Drugs & Organics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹63.28, compared to a current price of ₹28.79 — trading 54.5% below its estimated fair value. The current FCF Margin % is 0.00%. Mangalam Drugs & Organics' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?
Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued.
The current stock price of ₹28.79 is trading 54.5% below its estimated GF Value™ of ₹63.28.
GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.
Key valuation signals for NSE:MANGALAM:
FCF Margin %: 0.00%
GF Value™: ₹63.28 vs. price of ₹28.79 (54.5% below fair value)
No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score
Get the complete analysis for NSE:MANGALAM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MANGALAM has been successfully added to your 
